DK2183263T3 - Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer - Google Patents
Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorerInfo
- Publication number
- DK2183263T3 DK2183263T3 DK08826634.1T DK08826634T DK2183263T3 DK 2183263 T3 DK2183263 T3 DK 2183263T3 DK 08826634 T DK08826634 T DK 08826634T DK 2183263 T3 DK2183263 T3 DK 2183263T3
- Authority
- DK
- Denmark
- Prior art keywords
- transporter
- inhibitors
- preparation
- methods
- compounds useful
- Prior art date
Links
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95212207P | 2007-07-26 | 2007-07-26 | |
| PCT/US2008/070250 WO2009014970A1 (en) | 2007-07-26 | 2008-07-17 | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2183263T3 true DK2183263T3 (da) | 2012-01-30 |
Family
ID=39877996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08826634.1T DK2183263T3 (da) | 2007-07-26 | 2008-07-17 | Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8026347B2 (da) |
| EP (1) | EP2183263B1 (da) |
| JP (2) | JP5653213B2 (da) |
| KR (1) | KR101663324B1 (da) |
| CN (1) | CN101801989B (da) |
| AR (2) | AR067701A1 (da) |
| AT (1) | ATE530558T1 (da) |
| AU (1) | AU2008279424B2 (da) |
| CA (1) | CA2694029C (da) |
| CL (1) | CL2008002169A1 (da) |
| CO (1) | CO6260141A2 (da) |
| DK (1) | DK2183263T3 (da) |
| EA (1) | EA017411B1 (da) |
| EC (1) | ECSP109987A (da) |
| ES (1) | ES2375800T3 (da) |
| IL (1) | IL203209A (da) |
| NZ (1) | NZ582536A (da) |
| PL (1) | PL2183263T3 (da) |
| PT (1) | PT2183263E (da) |
| TW (2) | TWI419886B (da) |
| UA (1) | UA107175C2 (da) |
| WO (1) | WO2009014970A1 (da) |
| ZA (1) | ZA201000219B (da) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| AU2009270936B2 (en) | 2008-07-15 | 2014-12-18 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
| TWI472521B (zh) * | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| EA021983B1 (ru) | 2009-11-02 | 2015-10-30 | Пфайзер Инк. | Производные диоксабицикло[3.2.1]октан-2,3,4-триола |
| CN102711738A (zh) | 2009-11-13 | 2012-10-03 | 百时美施贵宝公司 | 质量得以减小的二甲双胍制剂 |
| EP3315124B1 (en) | 2009-11-13 | 2021-01-06 | Astrazeneca AB | Bilayer tablet formulations |
| JP5784623B2 (ja) | 2009-11-13 | 2015-09-24 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 速放性錠剤製剤 |
| TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
| WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| CN103370064A (zh) | 2010-09-03 | 2013-10-23 | 百时美施贵宝公司 | 使用水溶性抗氧化剂的药物制剂 |
| CA2826391C (en) | 2011-02-01 | 2017-01-24 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
| WO2012165914A2 (en) | 2011-06-01 | 2012-12-06 | Green Cross Corporation | Novel diphenylmethane derivatives as sglt2 inhibitors |
| BR112013031032A2 (pt) | 2011-06-03 | 2016-11-29 | Boehringer Ingelheim Int | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos |
| US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| PL3489226T3 (pl) * | 2012-11-20 | 2021-08-02 | Lexicon Pharmaceuticals, Inc. | Inhibitory kotransportera glukozowo-sodowego 1 |
| DK2981269T3 (da) | 2013-04-04 | 2023-10-23 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af stofskifteforstyrrelser hos hestedyr |
| WO2015043511A1 (en) | 2013-09-27 | 2015-04-02 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
| WO2015051484A1 (en) | 2013-10-12 | 2015-04-16 | Theracos, Inc. | Preparation of hydroxy-benzylbenzene derivatives |
| MX376097B (es) | 2013-12-17 | 2025-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Inhibidores de sglt2 para usarse en el tratamiento o prevención de trastornos metabólicos en animales felinos. |
| CA2932674C (en) | 2014-01-23 | 2023-01-24 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
| FI3721882T3 (fi) | 2014-04-01 | 2024-09-24 | Boehringer Ingelheim Vetmedica Gmbh | Aineenvaihduntahäiriöiden hoito hevoseläimissä |
| EP4403230A3 (en) | 2014-09-25 | 2025-01-08 | Boehringer Ingelheim Vetmedica GmbH | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| JP6727419B2 (ja) * | 2016-05-25 | 2020-07-22 | クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド | ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途 |
| WO2017206827A1 (zh) * | 2016-05-28 | 2017-12-07 | 山东轩竹医药科技有限公司 | 钠-葡萄糖协同转运蛋白2抑制剂的晶型 |
| MX392177B (es) | 2016-06-17 | 2025-03-19 | Daewoong Pharmaceutical Co Ltd | Metodo para producir derivado de difenilmetano |
| BR112019005930A2 (pt) | 2016-10-19 | 2019-06-11 | Boehringer Ingelheim Int | combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas |
| CN107540685B (zh) * | 2017-09-04 | 2020-05-05 | 杭州科巢生物科技有限公司 | 一种Sotagliflozin的制备方法及其中间体 |
| US20210113561A1 (en) | 2018-04-17 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN108675976B (zh) * | 2018-05-14 | 2020-07-14 | 浙江宏元药业股份有限公司 | 一种6-卤代葡萄糖碳苷及其制备方法和应用 |
| EP3838894B1 (en) | 2018-08-13 | 2024-03-13 | Daewoong Pharmaceutical Co., Ltd. | Method for producing intermediate useful for synethesis of sglt inhibitor |
| CN110818722B (zh) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
| US12213970B2 (en) | 2018-10-29 | 2025-02-04 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| DK3873600T5 (da) | 2018-10-29 | 2024-03-18 | Boehringer Ingelheim Int | Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf |
| EP3771480A1 (en) * | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
| EP4064854A1 (en) | 2019-11-28 | 2022-10-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
| JP7423800B2 (ja) | 2020-02-17 | 2024-01-29 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ネコにおける心臓疾患の予防および／または治療のためのｓｇｌｔ－２阻害剤の使用 |
| CN117715639A (zh) | 2021-07-28 | 2024-03-15 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途 |
| MX2024001184A (es) | 2021-07-28 | 2024-02-27 | Boehringer Ingelheim Vetmedica Gmbh | Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos. |
| US20240269105A1 (en) | 2021-07-28 | 2024-08-15 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
| WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| JP2026508912A (ja) | 2023-03-06 | 2026-03-13 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 液体医薬組成物、特に１種又は複数のｓｇｌｔ－２阻害剤を含む液体医薬組成物の送達のためのシステム |
| TW202508593A (zh) | 2023-05-24 | 2025-03-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防 |
| CN121175053A (zh) | 2023-05-24 | 2025-12-19 | 勃林格殷格翰动物保健有限公司 | 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防 |
| WO2025160910A1 (en) * | 2024-02-01 | 2025-08-07 | New Wish Biotechnology Wuxi Co., Ltd. | Indazole compound and pharmaceutical composition, preparation method and use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| ES2254376T3 (es) * | 2000-03-17 | 2006-06-16 | Kissei Pharmaceutical Co., Ltd. | Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados. |
| US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| AU2002223127A1 (en) * | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| WO2002083066A2 (en) * | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| US6562791B1 (en) * | 2002-03-29 | 2003-05-13 | Council Of Scientific And Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
| WO2003087119A1 (en) * | 2002-04-12 | 2003-10-23 | Achillion Pharmaceuticals, Inc. | METHOD FOR SYNTHESIZING β-L-FLUORO-2´,3´DIDEHYDROCYTIDINE (β-L-FD4C) |
| RU2322449C2 (ru) * | 2002-08-09 | 2008-04-20 | Тайсо Фармасьютикал Ко., Лтд. | ПРОИЗВОДНЫЕ АРИЛ 5-ТИО-β-D-ГЛЮКОПИРАНОЗИДА И ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА ПРИ ДИАБЕТЕ, СОДЕРЖАЩИЕ ИХ |
| BR0317929A (pt) * | 2003-01-03 | 2006-04-11 | Bristol Myers Squibb Co | métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila |
| US7368475B2 (en) * | 2003-03-12 | 2008-05-06 | Kemin Pharma Bvba | Furanose-type bicyclic carbohydrates with biological activity |
| ES2567571T3 (es) * | 2003-03-14 | 2016-04-25 | Astellas Pharma Inc. | Derivados de C-glucósido y sales de los mismos |
| WO2006018150A1 (de) * | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| ATE445608T1 (de) * | 2005-02-23 | 2009-10-15 | Boehringer Ingelheim Int | Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2) |
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| WO2008044268A1 (en) * | 2006-10-05 | 2008-04-17 | Panasonic Corporation | Transmitter apparatus and transmitting method |
| WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
| TWI472521B (zh) * | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
-
2008
- 2008-07-17 AU AU2008279424A patent/AU2008279424B2/en active Active
- 2008-07-17 EA EA201070186A patent/EA017411B1/ru not_active IP Right Cessation
- 2008-07-17 PL PL08826634T patent/PL2183263T3/pl unknown
- 2008-07-17 WO PCT/US2008/070250 patent/WO2009014970A1/en not_active Ceased
- 2008-07-17 UA UAA201002095A patent/UA107175C2/ru unknown
- 2008-07-17 JP JP2010518296A patent/JP5653213B2/ja active Active
- 2008-07-17 AT AT08826634T patent/ATE530558T1/de active
- 2008-07-17 CA CA2694029A patent/CA2694029C/en active Active
- 2008-07-17 EP EP08826634A patent/EP2183263B1/en active Active
- 2008-07-17 NZ NZ582536A patent/NZ582536A/en unknown
- 2008-07-17 CN CN200880100489.2A patent/CN101801989B/zh active Active
- 2008-07-17 KR KR1020107001659A patent/KR101663324B1/ko active Active
- 2008-07-17 ES ES08826634T patent/ES2375800T3/es active Active
- 2008-07-17 PT PT08826634T patent/PT2183263E/pt unknown
- 2008-07-17 US US12/174,722 patent/US8026347B2/en active Active
- 2008-07-17 DK DK08826634.1T patent/DK2183263T3/da active
- 2008-07-21 TW TW097127665A patent/TWI419886B/zh active
- 2008-07-21 TW TW102129521A patent/TWI506024B/zh active
- 2008-07-24 CL CL2008002169A patent/CL2008002169A1/es unknown
- 2008-07-25 AR ARP080103246A patent/AR067701A1/es active IP Right Grant
-
2010
- 2010-01-10 IL IL203209A patent/IL203209A/en active IP Right Grant
- 2010-01-12 ZA ZA2010/00219A patent/ZA201000219B/en unknown
- 2010-02-23 EC EC2010009987A patent/ECSP109987A/es unknown
- 2010-02-25 CO CO10022864A patent/CO6260141A2/es not_active Application Discontinuation
-
2011
- 2011-08-11 US US13/207,576 patent/US8293878B2/en active Active
-
2013
- 2013-08-28 JP JP2013176646A patent/JP5764174B2/ja active Active
-
2018
- 2018-08-03 AR ARP180102213 patent/AR112669A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2183263T3 (da) | Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer | |
| DK2089361T3 (da) | Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse | |
| EP2192838A4 (en) | HETEROCYCLIC NEKROPTOSIS HEMMER | |
| DK3428148T3 (da) | Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf | |
| DK2099796T3 (da) | Aza-indolyl-forbindelser og fremgangsmåder for anvendelse | |
| DK2414507T3 (da) | Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder | |
| DK2229360T3 (da) | Indolinonderivater og fremgangsmåde til deres fremstilling | |
| HRP20150003T1 (xx) | Sastavi inhibitora dpp-iv | |
| CY2014012I2 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
| DK2015754T3 (da) | Anvendelse af dpp-iv-inhibitorer | |
| DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
| DK3252057T3 (da) | Multicykliske forbindelser og fremgangsmåder til anvendelse deraf | |
| HRP20170222T1 (hr) | Kristalni oblik karbamoil-cikloheksan derivata | |
| DK1924577T3 (da) | Substituerede benzimidazoler og fremgangsmåder til fremstilling | |
| DK1981875T3 (da) | Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase | |
| DK2029746T3 (da) | Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese | |
| EP2299999A4 (en) | STAT3 INHIBITORS | |
| DK1979326T3 (da) | Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase | |
| NO20076533L (no) | Fremgangsmåte og system for klokkedriftskompensering | |
| NO20085219L (no) | Koplingsarrangement og fremgangsmate for forspent sammenkopling | |
| DK2445912T3 (da) | Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme | |
| DK2316010T3 (da) | Vævskassette og fremgangsmåde til fremstilling af vævsprøver | |
| DK2019090T3 (da) | Substitueret beta-phenyl-alfa-hydroxypropansyre, fremgangsmåde til syntese og anvendelse deraf | |
| DK1884507T3 (da) | Fremgangsmåde til fremstilling af glycerol | |
| DK2192117T3 (da) | Organisk aminsalt af 6-fluor-3-hydroxy-2-pyrazincarbonitril og fremgangsmåde til fremstilling deraf |